Bernt Johan von Scholten1, Henrik Reinhard2, Tine W Hansen2, Jens Oellgaard2,3,4, Hans-Henrik Parving5, Peter K Jacobsen6, Peter Rossing2,7,8. 1. Steno Diabetes Center, Niels Steensens Vej 1, 2820, Gentofte, Denmark. bjos@steno.dk. 2. Steno Diabetes Center, Niels Steensens Vej 1, 2820, Gentofte, Denmark. 3. Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. 4. Department of Endocrinology, Slagelse Hospital, Slagelse, Denmark. 5. Department of Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 6. Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark. 7. The Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. 8. Faculty of Health, Aarhus University, Aarhus, Denmark.
Abstract
AIMS/HYPOTHESIS: We evaluated two urinary biomarkers reflecting different aspects of renal pathophysiology as potential determinants of incident cardiovascular disease (CVD), all-cause mortality and a reduced estimated GFR (eGFR) in patients with type 2 diabetes and microalbuminuria but without clinical features of coronary artery disease. METHODS: In a prospective study of 200 patients, all received multifactorial treatment. Baseline measurements of urinary hepatocyte growth factor (HGF) and adiponectin were available for 191 patients. Cox models were adjusted for sex, age, LDL-cholesterol, smoking, HbA1c, plasma creatinine, systolic BP and urinary AER (UAER). The pre-defined endpoint of chronic kidney disease progression was a decline in the eGFR of >30% during follow-up. HRs per 1 SD increment of log-transformed values are presented. RESULTS: Patients had a mean ± SD age of 59 ± 9 years with a median (interquartile range) UAER of 103 (39-230) mg/24 h. During a median 6.1 years of follow-up, there were 40 incident CVD events, 26 deaths and 42 patients reached the pre-defined chronic kidney disease progression endpoint after 4.9 years (median). Higher urinary HGF was a determinant of CVD in unadjusted (HR 1.9 [95% CI 1.3, 2.8], p = 0.001) and adjusted (HR 2.0 [95% CI 1.2, 3.2], p = 0.004) models, and of all-cause mortality in unadjusted (HR 2.3 [95% CI 1.3, 3.9], p = 0.003) and adjusted (HR 2.5 [95% CI 1.3, 4.8], p = 0.005) models. A higher adiponectin level was associated with CVD in unadjusted (HR 1.4 [95% CI 1.0, 1.9], p = 0.04) and adjusted (HR 1.4 [95% CI 1.1, 2.3], p = 0.013) models, and with a decline in the eGFR of >30% in unadjusted (HR 1.6 [95% CI 1.2, 2.2], p = 0.008) and adjusted (HR 1.5 [95% CI 1.1, 2.2], p = 0.007) models. CONCLUSIONS/ INTERPRETATION: In patients with type 2 diabetes and microalbuminuria receiving multifactorial treatment, higher urinary HGF was associated with incident CVD and all-cause mortality, and higher adiponectin was associated with CVD and deterioration in renal function.
AIMS/HYPOTHESIS: We evaluated two urinary biomarkers reflecting different aspects of renal pathophysiology as potential determinants of incident cardiovascular disease (CVD), all-cause mortality and a reduced estimated GFR (eGFR) in patients with type 2 diabetes and microalbuminuria but without clinical features of coronary artery disease. METHODS: In a prospective study of 200 patients, all received multifactorial treatment. Baseline measurements of urinary hepatocyte growth factor (HGF) and adiponectin were available for 191 patients. Cox models were adjusted for sex, age, LDL-cholesterol, smoking, HbA1c, plasma creatinine, systolic BP and urinary AER (UAER). The pre-defined endpoint of chronic kidney disease progression was a decline in the eGFR of >30% during follow-up. HRs per 1 SD increment of log-transformed values are presented. RESULTS:Patients had a mean ± SD age of 59 ± 9 years with a median (interquartile range) UAER of 103 (39-230) mg/24 h. During a median 6.1 years of follow-up, there were 40 incident CVD events, 26 deaths and 42 patients reached the pre-defined chronic kidney disease progression endpoint after 4.9 years (median). Higher urinary HGF was a determinant of CVD in unadjusted (HR 1.9 [95% CI 1.3, 2.8], p = 0.001) and adjusted (HR 2.0 [95% CI 1.2, 3.2], p = 0.004) models, and of all-cause mortality in unadjusted (HR 2.3 [95% CI 1.3, 3.9], p = 0.003) and adjusted (HR 2.5 [95% CI 1.3, 4.8], p = 0.005) models. A higher adiponectin level was associated with CVD in unadjusted (HR 1.4 [95% CI 1.0, 1.9], p = 0.04) and adjusted (HR 1.4 [95% CI 1.1, 2.3], p = 0.013) models, and with a decline in the eGFR of >30% in unadjusted (HR 1.6 [95% CI 1.2, 2.2], p = 0.008) and adjusted (HR 1.5 [95% CI 1.1, 2.2], p = 0.007) models. CONCLUSIONS/ INTERPRETATION: In patients with type 2 diabetes and microalbuminuria receiving multifactorial treatment, higher urinary HGF was associated with incident CVD and all-cause mortality, and higher adiponectin was associated with CVD and deterioration in renal function.
Authors: Nicolae M Panduru; Markku Saraheimo; Carol Forsblom; Lena M Thorn; Daniel Gordin; Johan Wadén; Nina Tolonen; Angelika Bierhaus; Per M Humpert; Per-Henrik Groop Journal: Diabetes Care Date: 2015-02-26 Impact factor: 19.112
Authors: C Forsblom; M C Thomas; J Moran; M Saraheimo; L Thorn; J Wadén; D Gordin; J Frystyk; A Flyvbjerg; P-H Groop Journal: J Intern Med Date: 2011-06-23 Impact factor: 8.989
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: Bernt Johan von Scholten; Henrik Reinhard; Tine Willum Hansen; Morten Lindhardt; Claus Leth Petersen; Niels Wiinberg; Peter Riis Hansen; Hans-Henrik Parving; Peter Karl Jacobsen; Peter Rossing Journal: Cardiovasc Diabetol Date: 2015-05-21 Impact factor: 9.951
Authors: Claudia Menzaghi; Min Xu; Lucia Salvemini; Concetta De Bonis; Giuseppe Palladino; Tao Huang; Massimiliano Copetti; Yan Zheng; Yanping Li; Grazia Fini; Frank B Hu; Simonetta Bacci; Lu Qi; Vincenzo Trischitta Journal: Cardiovasc Diabetol Date: 2014-09-10 Impact factor: 9.951
Authors: Emilie H Zobel; Bernt Johan von Scholten; Henrik Reinhard; Frederik Persson; Tom Teerlink; Tine W Hansen; Hans-Henrik Parving; Peter K Jacobsen; Peter Rossing Journal: Cardiovasc Diabetol Date: 2017-07-11 Impact factor: 9.951
Authors: Marie Frimodt-Møller; Bernt Johan von Scholten; Henrik Reinhard; Peter Karl Jacobsen; Tine Willum Hansen; Frederik Ivar Persson; Hans-Henrik Parving; Peter Rossing Journal: PLoS One Date: 2018-04-26 Impact factor: 3.240
Authors: Yong Chul Kim; Jung Nam An; Jin Hyuk Kim; Young-Wook Choi; Sohee Oh; Sang Ho Kwon; Mi-Young Lee; Junghun Lee; Jae-Gyun Jeong; Chun Soo Lim; Yon Su Kim; Seung Hee Yang; Jung Pyo Lee Journal: Sci Rep Date: 2018-08-24 Impact factor: 4.379